When can Tranexamic acid (TXA) be administered for vaginal bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Tranexamic acid (TXA) can be given for vaginal bleeding when the bleeding is heavy, particularly in cases of postpartum hemorrhage, as soon as possible within 3 hours of birth at a dose of 1 gram IV over 10 minutes, with a second dose of 1 gram if bleeding continues after 30 minutes or restarts within 24 hours 1.

Key Considerations

  • The most recent and highest quality study recommends the use of TXA in postpartum hemorrhage within 3 hours of birth 1.
  • The dose of TXA for postpartum hemorrhage is 1 gram IV over 10 minutes, with a second dose of 1 gram if bleeding continues after 30 minutes or restarts within 24 hours 1.
  • TXA is contraindicated in patients with active thromboembolic disease, history of thrombosis, or severe renal impairment.
  • Side effects of TXA may include nausea, vomiting, and diarrhea.
  • It's essential to rule out underlying pathologies such as endometrial cancer, fibroids, or coagulopathies before attributing vaginal bleeding solely to menorrhagia.

Administration and Monitoring

  • TXA should be given as part of the standard treatment packages for postpartum hemorrhage, in accordance with WHO guidelines 1.
  • Health facilities providing emergency obstetric care should have the necessary supplies and trained staff to administer TXA safely by intravenous infusion 1.
  • Treatment with TXA should be avoided in women with a clear contraindication to antifibrinolytic therapy, such as a known thromboembolic event during pregnancy 1.

From the Research

TXa Administration for Vaginal Bleeding

  • TXa can be given for vaginal bleeding in the following situations:
    • Heavy menstrual bleeding: TXa has been shown to reduce menstrual blood loss by 26%-60% and improve the quality of life of women treated for heavy menstrual bleeding 2
    • Postpartum hemorrhage (PPH) after vaginal delivery: TXa reduces the risk of hysterectomy and does not increase the risk of thrombotic events in women with established primary PPH after vaginal delivery 3
  • The recommended oral dosage of TXa for heavy menstrual bleeding is 3.9-4 g/day for 4-5 days starting from the first day of the menstrual cycle 2
  • For PPH after vaginal delivery, a dose of 1 g TXa can be given, with a second dose of 1 g if bleeding continues after 30 minutes 3
  • TXa can also be used to prevent PPH after vaginal birth, although the evidence is not conclusive, and it may result in little to no difference in blood loss ≥ 500 mL and likely little to no difference in blood loss ≥ 1000 mL or the risk of severe morbidity 4
  • Adverse effects of TXa are few and mainly mild, with no evidence of an increase in the incidence of thrombotic events associated with its use 2
  • Contraindications for TXa use include active thromboembolic disease, history of thrombosis or thromboembolism, or an intrinsic risk for thrombosis or thromboembolism 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2020

Research

Tranexamic acid for preventing postpartum haemorrhage after vaginal birth.

The Cochrane database of systematic reviews, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.